New Breast Cancer Clinical Data Accepted For Presentation At San Antonio Breast Cancer Symposium

Predictive medicine company
PreMD Inc. (TSX: PMD; Amex: PME) announced that an abstract entitled,
'Galactose oxidase Schiff's reactivity is higher in nipple aspirate fluid
from cancerous breasts than from healthy patients' has been accepted for
presentation at the 30th Annual San Antonio Breast Cancer Symposium
(SABCS). The SABCS is a leading international symposium for physicians and
healthcare researchers involved in breast cancer research.


"We are extremely pleased and honored that this abstract has been
accepted for presentation at this influential symposium," said Brent
Norton, president and chief executive officer of PreMD Inc. "This study
provides valuable clinical insight as to how women with unilateral breast
cancer may benefit from testing with galactose oxidase Schiff's (GOS)
reactivity. This presentation further strengthens our clinical data and our
entire cancer franchise, which we are progressively developing."



GOS reactivity is significantly different between nipple aspirate fluid
(NAF) taken from cancerous versus non-cancerous breasts of women with
unilateral breast cancer. This study extends these findings and evaluates
GOS reactivity in healthy control patients.



The lead author on the study is Dr. Anees B. Chagpar from the
University of Louisville. The San Antonio Breast Cancer Symposium takes
place on December 13-16, 2007, in San Antonio, Texas.



About PreMD Inc.



PreMD Inc. is a leader in predictive medicine, dedicated to developing
rapid, non-invasive tests for the early detection of life-threatening
diseases. PreMD's cardiovascular products are branded as PREVU(x) Skin
Cholesterol Test, to be marketed and distributed by AstraZeneca. The
company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a
breast cancer test. PreMD's head office is located in Toronto, Ontario and
its research and product development facility is at McMaster University in
Hamilton, Ontario. For further information, please visit premdinc.
For more information about PREVU(x), please visit prevu.



This press release contains forward-looking statements. These
statements involve known and unknown risks and uncertainties, which could
cause the Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the success of a plan for regaining compliance with certain
continued listing standards of the American Stock Exchange, successful
development or marketing of the Company's products, the competitiveness of
the Company's products if successfully commercialized, the lack of
operating profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, product
liability, reliance on third-party manufacturers, the ability of the
Company to take advantage of business opportunities, uncertainties related
to the regulatory process, and general changes in economic conditions.



In addition, while the Company routinely obtains patents for its
products and technology, the protection offered by the Company's patents
and patent applications may be challenged, invalidated or circumvented by
our competitors and there can be no guarantee of our ability to obtain or
maintain patent protection for our products or product candidates.



Investors should consult the Company's quarterly and annual filings
with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned not to rely on these forward-looking
statements. PreMD is providing this information as of the date of this
press release and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of
new information, future events or otherwise.



(x) Trademark


PreMD Inc.

premdinc